Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-81201887
- Development stage
- Phase 2
- Lead developer
- Janssen Research & Development
- Modality
- Gene Therapies
- Administration
- Ophthalmic
01
Overview
JNJ-81201887 (formerly JNJ-1887 or AAVCAGsCD59) is an investigational gene therapy being developed by Janssen Research & Development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The therapy utilizes a recombinant adeno-associated virus serotype 2 (AAV2) vector to deliver a transgene encoding a soluble form of CD59 (sCD59). CD59 is a naturally occurring cell surface protein that protects cells from complement-mediated lysis by inhibiting the assembly of the membrane attack complex (MAC), the terminal step of the complement cascade. By increasing the local expression of sCD59 in the retina through a single intravitreal injection, JNJ-81201887 aims to protect retinal pigment epithelial cells and photoreceptors from complement-driven destruction, thereby slowing the progression of GA lesions and preserving vision.
- Other names
- HMR59HMR-59HMR 59
02
Targets
C5
Beyond the preview
Go deeper on JNJ-81201887.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-81201887.